Wells Fargo & Company MN boosted its stake in Enanta Pharmaceuticals (NASDAQ:ENTA) by 28.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,388 shares of the biotechnology company’s stock after purchasing an additional 5,191 shares during the quarter. Wells Fargo & Company MN’s holdings in Enanta Pharmaceuticals were worth $1,373,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. LS Investment Advisors LLC increased its holdings in Enanta Pharmaceuticals by 56.8% in the fourth quarter. LS Investment Advisors LLC now owns 3,714 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 1,345 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in Enanta Pharmaceuticals in the fourth quarter valued at about $286,000. Crossmark Global Holdings Inc. increased its holdings in Enanta Pharmaceuticals by 34.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 8,300 shares of the biotechnology company’s stock valued at $487,000 after purchasing an additional 2,130 shares during the last quarter. Unison Advisors LLC bought a new stake in Enanta Pharmaceuticals in the fourth quarter valued at about $523,000. Finally, Chicago Equity Partners LLC bought a new stake in Enanta Pharmaceuticals in the fourth quarter valued at about $733,000. Institutional investors and hedge funds own 73.26% of the company’s stock.
In other Enanta Pharmaceuticals news, Treasurer Paul J. Mellett sold 9,000 shares of the stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $86.48, for a total value of $778,320.00. Following the completion of the sale, the treasurer now directly owns 96,458 shares in the company, valued at $8,341,687.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Nathalie Adda sold 4,225 shares of the stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $85.58, for a total value of $361,575.50. Following the completion of the sale, the vice president now owns 10,225 shares of the company’s stock, valued at $875,055.50. The disclosure for this sale can be found here. 10.56% of the stock is owned by corporate insiders.
A number of equities research analysts recently commented on the company. Royal Bank of Canada downgraded Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 price objective for the company. in a report on Tuesday, January 2nd. JPMorgan Chase downgraded Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday, February 8th. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 10th. BidaskClub downgraded Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 10th. Finally, ValuEngine upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Four analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $57.80.
Shares of Enanta Pharmaceuticals stock opened at $87.49 on Friday. Enanta Pharmaceuticals has a 1 year low of $29.46 and a 1 year high of $95.91. The stock has a market capitalization of $1,653.18, a price-to-earnings ratio of 44.94 and a beta of 1.07.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.73. Enanta Pharmaceuticals had a return on equity of 13.33% and a net margin of 26.35%. The company had revenue of $38.11 million during the quarter, compared to the consensus estimate of $27.26 million. sell-side analysts predict that Enanta Pharmaceuticals will post 1.04 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Enanta Pharmaceuticals (ENTA) Position Raised by Wells Fargo & Company MN” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/21/enanta-pharmaceuticals-enta-position-raised-by-wells-fargo-company-mn.html.
Enanta Pharmaceuticals Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.